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i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 4 7e3 5 2348fluid removal, it establishes the fact that optimal diuretic
dosing as advocated by the authors, is still a better initial
approach in diuretic responsive patients of decompensated
heart failure with persistent fluid overload.
The result of this trial should not undermine the utility of
ultrafiltration which still remains important treatment strat-
egy for diuretic unresponsive patients, rather sub serve for
conducting future studies with aim of finding adequate
ultrafiltration rates that may produce better results.r e f e r e n c e s
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Background: The multicenter PROTECT AF study (Watch-
man Left Atrial Appendage System for Embolic Protection in
Patients With Atrial Fibrillation) was conducted to determine
whether percutaneous left atrial appendage closure with a
filter device (Watchman) was noninferior to warfarin for
stroke prevention in atrial fibrillation.
Methods and results: Patients (n ¼ 707) with nonvalvular
atrial fibrillation and at least 1 risk factor (age >75 years,
hypertension, heart failure, diabetes, or prior stroke/transient
ischemic attack) were randomized to either the Watchman
device (n ¼ 463) or continued warfarin (n ¼ 244) in a 2:1 ratio.
After device implantation, warfarin was continued for z45
days, followed by clopidogrel for 4.5 months and lifelong
aspirin. Study discontinuation rates were 15.3% (71/463) and
22.5% (55/244) for the Watchman and warfarin groups,
respectively. The time in therapeutic range for the warfarin
group was 66%. The composite primary efficacy endpoint
included stroke, systemic embolism, and cardiovascular death,
and the primary analysis was by intention to treat. After 1588patient-years of follow-up (mean 2.3  1.1 years), the primary
efficacy event rates were 3.0% and 4.3% (percent per 100
patient-years) in the Watchman and warfarin groups, respec-
tively (relative risk, 0.71; 95% confidence interval, 0.44%e1.30%
per year), which met the criteria for noninferiority (probability
of noninferiority >0.999). There were more primary safety
events in the Watchman group (5.5% per year; 95% confidence
interval, 4.2%e7.1% per year) than in the control group (3.6%
per year; 95% confidence interval, 2.2%e5.3% per year; relative
risk, 1.53; 95% confidence interval, 0.95e2.70).
Conclusions: The “local” strategy of left atrial appendage
closure is noninferior to “systemic” anticoagulation with
warfarin. PROTECT AF has, for the first time, implicated the
left atrial appendage in the pathogenesis of stroke in atrial
fibrillation.1. Perspective
Balancing the benefits incurred by preventing stroke and sys-
temic embolism versus risks of major bleed has been the cor-
nerstone of developing effective anticoagulation strategies in
atrial fibrillation (AF). Recently approved oral anticoagulants
when compared to warfarin showed reduction in incidence of
stroke/embolism by 20e34%, ICH by 50e70%. However, rate of
major bleed has remained same with Dabigatran and Rivarox-
aban, and only Apixaban showing 30% reduction in such
events.1 The data from these trials highlight an important fact,
that an anticoagulant will always predispose an individual to
risk of bleeding and fatal hemorrhagic strokes no matter how
good it is. The recently published 2.3-year follow-up of the
PROTECTAF2 trial which looked at the strategy of occluding the
leftatrial appendage (LAA), isvery importantas itmarks thefirst
attempt of devisingways of preventing thromboembolic events
without subjecting individuals to excessive bleeding risk. In this
unblinded, multicenter study, 707 patients of nonvalvular AF
(CHADS2 score of1)were randomized to either theWatchman
device (n ¼ 463) or warfarin (n ¼ 244) in a 2:1 ratio. Patients in
device arm received warfarin for minimum of 45 days (more as
guided by TEE), dual antiplatelet for 4.5 months thereafter and
followed by lifelong aspirin. Eighty seven percent of patients
receiving the devicewere able to discontinuewarfarin at day 45
with number increasing to 95% by year-end.
The efficacy as assessed by composite of any stroke, car-
diovascular or unexplained death, or systemic embolism was
similar in both groups (3%/year in the device vs. 4.3%/year in
the controls) proving noninferiority.
Excessive bleeding and procedure related events occurred
more frequently in the device (5.5%) than in the control arm
(3.6%). While the incidence decreased over time in device
group it accrued in controls (post-procedure: 2.5%/year
versus 4.3%/year). Similarly, on long term follow-up lower
rate ofmajor bleeding in device group (RR 0.35) were observed.
The results indicate that after successful deployment, the
device proved to be superior to well controlled systemic
anticoagulation.
We believe that one of the biggest limitations of this study
is the relatively small number of patients enrolled as com-
pared to other studies involving new oral anticoagulants.
Drawing indirect conclusions seems inappropriate even
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 4 7e3 5 2 349though the authors of above study have found favorable
comparison between the device and new anticoagulants in
terms of follow-up, patient characteristics and time in ther-
apeutic range. Also, the study is not powered enough to
answer questions in specific subgroups (e.g. patients with
prior history of TIA/stroke).
We believe that further studies with large number and long
term follow-up will clarify whether use of such devices can be
generalized. If approved, this therapy will not only revolu-
tionize the management of AF (by minimizing issues like
major bleed, drug interruption for surgical procedures and
compliance) but also design studies targeting patients deemed
in eligible to oral anticoagulation.r e f e r e n c e s
1. Tan Ru San, Mark Yan Yee Chan, Teo Wee Siong, et al. Stroke
prevention in atrial fibrillation: understanding the new oral
anticoagulants dabigatran, rivaroxaban, and apixaban.
Thrombosis 2012. http://dx.doi.org/10.1155/2012/108983.
2. Vivek Y. Reddy, Shephal K. Doshi, Horst Sievert, et al.
Percutaneous left atrial appendage closure for stroke
prophylaxis in patients with atrial fibrillation: 2.3 year
follow-up of the PROTECT AF trial. http://dx.doi.org/10.1161/
CIRCULATIONAHA.112.114389.
Contributed by
Gaurav Mohan
Naved Aslam
Gurpreet Singh Wander*
Dayanand Medical College & Hospital Unit,
Hero DMC Heart Institute, India
*Corresponding author.
E-mail address: drgswander@yahoo.com (G.S. Wander)Hiroki Mizoguchi, Aiko Ogawa, Mitsuru Munemasa,Hiroshi Mikouchi, Hiroshi Ito, Hiromi Matsubara, Refined
balloon pulmonary angioplasty for inoperable patients with
chronic thromboembolic pulmonary hypertension. Circ Car-
diovasc Interv 2012;5:748e755.
Background: Although balloon pulmonary angioplasty
(BPA) for inoperable patients with chronic thromboembolic
pulmonary hypertension was first reported over a decade ago,
its clinical application has been restricted because of limited
efficacy and complications. We have refined the procedure of
BPA to maximize its clinical efficacy.
Methods and results: Sixty-eight consecutive patients
with inoperable chronic thromboembolic pulmonary
hypertension (CTEPH) underwent BPA. We evaluated pul-
monary artery diameters and determined the appropriate
balloon size by using intravascular ultrasound. We per-
formed BPA in a staged fashion over multiple, separate
procedures to maximize efficacy and reduce the risk of
reperfusion pulmonary injury. A total of 4 (2e8) sessions
were performed in each patient, and the number of vessels
dilated per session was 3 (1e14). The World Health Organ-
ization functional class improved from 3 to 2 (p < 0.01), andmean pulmonary arterial pressure was decreased from
45.4  9.6 to 24.0  6.4 mm Hg (p < 0.01). One patient died
because of right heart failure 28 days after BPA. During
follow-up for 2.2  1.4 years after the final BPA, another
patient died of pneumonia, and the remaining 66 patients
are alive. In 57 patients who underwent right heart cathe-
terization at follow-up, improvement of mean pulmonary
arterial pressure was maintained (24.0  5.8 mmHg at
1.0  0.9 years). Forty-one patients (60%) developed reper-
fusion pulmonary injury after BPA, but mechanical ven-
tilation was required in only 4 patients.
Conclusions: Our refined BPA procedure improves clinical
status and hemodynamics of inoperable patients with chronic
thromboembolic pulmonary hypertension, with a low mor-
tality. A refined BPA procedure could be considered as a
therapeutic approach for patients with inoperable chronic
thromboembolic pulmonary hypertension.1. Perspective
Pulmonary endarterectomy is the only potentially curative
treatment for CTEPH. However, nearly one-third patients of
CTEPH are not fit for this procedure because of various rea-
sons. Although vasodilator therapy such as epoprostenol has
been tried in such cases, they have very limited efficacy in
terms of functional class or hemodynamics. Considering the
highmortality of such patients when untreated an alternative
therapeutic option is required. It is in this context that BPA can
play some role.
BPA for a patient with CTEPH was first reported in 1988. In
2001, Feinstein et al reported improvement in hemodynamics
in 18 inoperable cases of CTEPH. However, even after more
than 20 years after the first report of BPA, it is still not widely
accepted as a therapeutic option for inoperable patients with
CTEPH because of the following reasons: 1) insufficient
improvement in hemodynamics after BPA, 2) inaccurate esti-
mate of balloon size based only on angiographic findings
thereby leading to pulmonary artery rupture and 3) high inci-
dence of pulmonary reperfusion injury andpulmonary edema.
The present study has tried to overcome these limitations
by refining BPA by use of the following measures: 1) use of
IVUS to provide more accurate estimates of the diameters of
target pulmonary arteries, thereby preventing rupture of
pulmonary arteries to a great extent, 2) BPA done in a staged
fashion over multiple procedures to reduce the risk of pul-
monary reperfusion injury while still achieving an effective
therapeutic result. Also, in this study, a soft-tipped 6F guiding
catheter, a thinner 0.014-inch wire and a low profile balloon
were used, which potentiated the opening of completely
obstructed lesions with a lower risk of perforation. All these
armamentarium are commercially available and this proce-
dure can be performed in any catheterization laboratory.
After determination of the vessel diameter with IVUS, initial
dilatation was done with a 2 mm balloon and the diameter of
the balloon was gradually increased to a maximum size of
not more than 90% of the original vessel diameter. This
avoided rupture and dissection of the pulmonary artery. The
procedure was repeated in multiple sessions until a sufficient
amount of stenosis were dissolved. The more segments
